Comparing IM Cannabis (NASDAQ:IMCC) & Talphera (NASDAQ:TLPH)

IM Cannabis (NASDAQ:IMCC) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Volatility & Risk

IM Cannabis has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Talphera has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.

Profitability

This table compares IM Cannabis and Talphera’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-39.62%	N/A	-58.32%
Talphera	N/A	-87.28%	-51.36%

Earnings and Valuation

This table compares IM Cannabis and Talphera”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17 million	0.03	-$8.10 million	($60.66)	-0.02
Talphera	$1,000.00	56,318.01	-$14.29 million	($0.27)	-4.02

IM Cannabis has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 5.9% of IM Cannabis shares are owned by company insiders. Comparatively, 3.5% of Talphera shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for IM Cannabis and Talphera, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1	0	0	0	1.00
Talphera	1	1	2	0	2.25

Talphera has a consensus target price of $3.00, suggesting a potential upside of 176.50%. Given Talphera’s stronger consensus rating and higher possible upside, analysts plainly believe Talphera is more favorable than IM Cannabis.

Summary

Talphera beats IM Cannabis on 8 of the 14 factors compared between the two stocks.

About IM Cannabis

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

About Talphera

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.